TickerTalks
Browse all tickers →
TickerTalks›$NVAX
NVNVAX

Novavax, Inc.

Buzzing onWhy it's trendingMoving on elevated volumeStrong bullish X conversation
$NVAX·$1.4B·Biotechnology·Healthcare
$10.22+1.0%1Y+34.0%
Mentions · last 7 days
2026-08-23: 16 posts258+7%
Price updated 3m ago·X counts updated 10d ago
NVNVAX
$NVAXNovavax, Inc.
$10.22+1.01%258 posts+7%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NVAX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptAcceleratingAI verdict · as of 2026-09-02

The move is getting stronger, with heavier trading behind it.

The non-mRNA COVID royalty model plus Matrix-M oncology speculation, with 30% short interest as fuel.

Novavax makes a non-mRNA COVID vaccine (Nuvaxovid) and licenses its Matrix-M adjuvant technology, now increasingly to partners Sanofi and Takeda for the 2026-27 season. XFG-adapted Nuvaxovid was just approved in the US, EU, and Japan (8/28), and Matrix-M speculation on oncology use has driven the stock up 8% on the day.

  • The partnership royalty model is now real revenue: XFG-adapted Nuvaxovid approvals in the US, EU, and Japan on 8/28 secure royalty revenue via Sanofi and Takeda for the 2026-27 vaccination season — a mechanical revenue lane that scales without Novavax's own commercial burden.
  • The oncology optionality is the near-term speculative bet: sentiment repeatedly cites rumors of a "top-10 global pharma" partner for Matrix-M in oncology — unnamed, unconfirmed, but the kind of rumor that gets action given how depressed the stock has been.
  • Short interest is the tape's fuel: roughly 46M shares short (~30% of float) with unusual call buying and the argument that Novavax is the only non-mRNA COVID option — any positive Matrix-M oncology headline could turn the short interest into aggressive squeeze fuel.

The accelerating tape stays intact through the 2026-27 vaccination season revenue print and any Matrix-M partnership announcement. The 11/5 Q3 earnings are the next real catalyst; a confirmed Matrix-M pharma partner or a clean seasonal royalty guide extends the run. A rumor denial or missed royalty ramp breaks the setup back below $8.

Agrees with X sentimentThe X bull case — Sanofi/Takeda XFG partner approvals for 2026-27, ~46M shares short (~30% SI), unusual call buying, Matrix-M oncology unnamed 'top-10' pharma rumor, and the non-mRNA distinction — matches the setup. The lack of bear voices is honest but a reminder that rumor-driven speculation carries real risk when the partner never surfaces.

What to watch: 11/5 Q3 earnings and any Matrix-M partnership announcement. A confirmed oncology partner or a clean seasonal royalty guide extends the run; a rumor denial or missed royalty ramp breaks the setup back below $8.

On the calendar: 2026-11-05 - Q3 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment42 posts analyzed · as of 2026-09-01

Sentiment is strongly bullish, driven by partner approvals of XFG-adapted Nuvaxovid across the US, EU and Japan for the 2026-27 season, which secures royalty revenue via Sanofi and Takeda. Bulls stack on the short-squeeze setup with ~46M shares short (~30% SI), unusual call buying, and the argument that Novavax is the only non-mRNA COVID option. The core speculative bet is on Matrix-M adjuvant use in oncology, with rumors of an unnamed 'top-10 global pharma' partner. Skeptical takes are essentially absent.

Read the AI verdict + X sentiment for $NVAX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Novavax makes protein-based COVID-19 and influenza vaccines using its recombinant nanoparticle technology platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NVAX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $NVAX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+50.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-36.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-54.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
160%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
77.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-1.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.32$-0.38+15.8%
Q1 2026May 6, 2026$-0.06$-0.25+76.0%
Q4 2025Feb 26, 2026$0.11$-0.66+116.7%
Q3 2025Nov 6, 2025$-1.25$-1.08-15.7%
Next earningsThu, Nov 5·consensus EPS $-0.22

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$56.7M-76.3%74.9%-96.8%$-0.32$-74.1M
Q1 FY26$139.5M-79.1%78.0%-11.1%$-0.06$-33.7M
Q4 FY25$147.1M+66.6%82.9%14.3%$0.11$-41.6M
Q3 FY25$70.4M-16.6%69.5%-253%$-1.25$105.8M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$363.1M$265.6M – $443.2M-$0.73-$1.64 – $0.817
FY27$269.0M$189.9M – $333.5M-$0.15-$5.65 – $9.967
FY28$285.1M$143.1M – $394.1M$0.25-$0.47 – $1.026
FY29$431.3M$275.8M – $590.0M$1.05$0.56 – $1.564
FY30$376.6M$240.8M – $515.3M$0.55$0.29 – $0.813

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.68%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+19.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+19.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 141.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today7.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.425-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 19 other (9 exempts · 9 awards · 1 inkind) in window

See when $NVAX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 238-K — Item 5.07: Shareholder vote
SC 13D/AActivist amendmentMay 15SC 13D/A
3New insider — initial holdingsApr 163
SC 13D/AActivist amendmentApr 8SC 13D/A
+ 12 other (4 13Gs · 2 earnings 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?247wallst.com·1d agoNovavax Stock Climbs Monday: What's Going On?benzinga.com·2d agoNovavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Seasongurufocus.com·5d agoNovavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Seasonprnewswire.com·5d agoUS FDA approves updated COVID vaccines for 2026-27 seasonreuters.com·6d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$MRNA$ALT$CELU$NWBO$SLS$AMLX$ABCL
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport